Vaxcyte, Inc. — Director's Dealing 2023

Dec 5, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2023-12-01

Reporting Person: Wassil Jim (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-01	Common Stock	M	3000	$2.42	Acquired	178935	Direct
2023-12-01	Common Stock	S	1067	$51.46	Disposed	177868	Direct
2023-12-01	Common Stock	S	1933	$52.509	Disposed	175935	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-01	Stock Option (right to buy)	$2.42	M	3000	Disposed	2029-12-16	Common Stock (3000)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $51.185 to $52.14. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $52.18 to $52.925. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.